Will This Obesity Biotech's Latest Scheme Boost Sales?
Drugmaker VIVUS has struggled to ramp up sales of its recently approved obesity medication Qsymia. With competition from Arena Pharmaceuticals and its partner Eisai looming once their drug Belviq clears DEA scheduling, VIVUS has launched the Save Now! program. In this video, health care analyst Max Macaluso discusses how this new program will impact VIVUS' business and how it might affect the competitive landscape of the obesity market.
Who will win the obesity drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.
Editor's note: This video was filmed on March 5, 2013.
The article Will This Obesity Biotech's Latest Scheme Boost Sales? originally appeared on Fool.com.Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.